Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.04.2016 | leitlinien für die praxis

Insulintherapie bei Diabetes mellitus

verfasst von: Monika Lechleitner, Michael Roden, Raimund Weitgasser, Bernhard Ludvik, Peter Fasching, Friedrich Hoppichler, Alexandra Kautzky-Willer, Guntram Schernthaner, Rudolf Prager, Thomas C. Wascher

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende Leitlinie nimmt Bezug auf die praktische Umsetzung der Insulintherapie bei Typ 1 und Typ 2 Diabetes. Die unterschiedlichen Formen der Insulintherapie sowie die Berechnung und Anpassung des Insulinbedarfs werden dargestellt.
Vorheriger Artikel Antihyperglykämische Therapie bei Diabetes mellitus Typ 2
Nächster Artikel Antihypertensive Therapie bei Diabetes mellitus
Literatur
1.
American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2015;38 Suppl 1:S41–S8.CrossRef
2.
Cheng A, Hanna A, Kader T, Richardson S. Insulin therapy in type 1 diabetes. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. 2008;46–52.
3.
The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
4.
Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–69.CrossRef
5.
6.
De Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria. Arch Intern Med. 2011;171:412–20.CrossRefPubMedPubMedCentral
7.
Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albrers JW, DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010;10:276–82.CrossRefPubMedPubMedCentral
8.
Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lechin JM, Lorenzi G, Zinman B, DCCT/EDIC Research Group. Diabetes controls and complications trial/epidemiology of diabetes intervention and complications study at 30 years: advances and contributions. Diabetes. 2013;62:3976–86.CrossRefPubMedPubMedCentral
9.
Nathan DM, Cleary PA, Backlund Yu, et al.; Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
10.
Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Perin P, Bruno G. QTc interval prolongation is independently associated with severe hypoglycaemia attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care. 2012;35:125–7.CrossRefPubMedPubMedCentral
11.
UK Prospective Diabetes Study (UKPDS Group). Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–52.CrossRef
12.
Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-year follow up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMed
13.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.CrossRefPubMed
14.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef
15.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMedCentral
16.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–4.CrossRefPubMed
17.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42.CrossRefPubMed
18.
Ismail-Beigi F, Moghissi E, Tikin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–9.CrossRefPubMed
19.
Lipska KJ, Ross JS, Miao Y, Shah NO, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA. Intern Med. 2015;175:356–62.CrossRefPubMedPubMedCentral
20.
Wong JC, Foster NC, Maahs DM, Raghinaru D, et al; T1D Exchange Clinic Network. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014;37:2702–4.
21.
Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005;165:1337–44.CrossRefPubMed
22.
Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A. Long-acting insulin analogies versus NPH-insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;18:CD005613.
23.
Jensen MG, Hansen M, Brock B, Rungby J. Differences between long-acting insulins fort the treatment of type 2 diabetes. Exp Opin Pharmacother. 2010;11:2027–35.CrossRef
24.
The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.CrossRef
25.
Riddle MC, Bolli GB, Ziemen M, et al. New insulin Glargin 300 Units/mL versus Glargine 100 Units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose controls and hypoglycemia in a 6-months randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–62CrossRefPubMed
26.
Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin Glargine 300 Units/mL versus Glargine 100 Units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose controls and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–43CrossRefPubMed
27.
Haahr H, Heise T. A review of the pharmacological properties of insulin deglutec and their clinical relevance. Clin Pharmacokinet. 2014;53:787–800.CrossRefPubMedPubMedCentral
28.
Vora J, Cariou B, Evans M, et al. Clinical use of insulin deglutec. Diabetes Res Clin Pract. 2015;109:19–31.CrossRefPubMed
29.
Becker RH, Dammen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units/ml provides a more even activity profile and prolonged glycemic control at study state compared with insulin glargine 100 units/ml. Diabetes Care. 2015;38:637–43.PubMed
30.
Smith U, Gale EM. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009;52:1699–708.CrossRefPubMed
31.
Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, et al. Risk of cancer in patients on insulin glargin and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55:51–62.CrossRefPubMedPubMedCentral
32.
Gristina V, Cupri MG, Torchio M, Mezzogori C, Cacciabue L, Panova M. Diabetes and cancer: a critical appraisal of the pathogenetic and therapeutic links. Biomed Rep. 2015;3:131–6.PubMedPubMedCentral
33.
Holman RR, Farmer AJ, Davies MJ, et al.; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.
34.
Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice- or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8:58–66.CrossRefPubMed
35.
Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol. 2012;8:425–33.CrossRefPubMed
36.
Goudswaard AN, Furlong NJ, Valk GD, Stolk RP, Ruiten GEHM. Insulin monotherapy versus combination of insulin with oral hypoglycemic agents in patients with type 2 diabetes. Cochrane Database Syst Rev. 2004;4:CD003418.PubMed
37.
Herman WH, Buse JB, Arakaki RF, Dungan KM, Jiang HH, Jacobson JG, Fahrbach JL. Concomitant oral antihyperglycemic agent use and associated outcomes after initiation of insulin therapy. Endocr Pract. 2011;17:563–7.CrossRefPubMed
38.
Donner T, Munoz M. Update on insulin therapy for type 2 diabetes. J Clin Endocrinol. 2012;97:1405–13.CrossRef
39.
Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 2012;344:e1771.CrossRefPubMed
40.
Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311:2288–96.CrossRefPubMedPubMedCentral
41.
Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124–36.CrossRefPubMed
42.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.CrossRefPubMed
43.
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potentail complications of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–93.CrossRefPubMed
44.
45.
Digenio A, Karve S, Candrilli SD, Dalal M. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. Postgrad Med. 2014;126:49–59.CrossRefPubMed
Metadaten
Titel
Insulintherapie bei Diabetes mellitus
verfasst von
Monika Lechleitner
Michael Roden
Raimund Weitgasser
Bernhard Ludvik
Peter Fasching
Friedrich Hoppichler
Alexandra Kautzky-Willer
Guntram Schernthaner
Rudolf Prager
Thomas C. Wascher
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0925-1

Weitere Artikel der Sonderheft 2/2016

Geschlechtsspezifische Aspekte für die klinische Praxis bei Prädiabetes und Diabetes mellitus

  • leitlinien für die praxis

Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen

  • Open Access
  • leitlinien für die praxis

Körperliche Aktivität und Training in der Prävention und Therapie des Typ 2 Diabetes mellitus

  • leitlinien für die praxis

Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung

  • leitlinien für die praxis

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications

  • Open Access
  • austrian lipid consensus

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2

  • leitlinien für die praxis